Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Melanoma: HELP
Articles by Paolo Rosina
Based on 3 articles published since 2009
(Why 3 articles?)
||||

Between 2009 and 2019, P. Rosina wrote the following 3 articles about Melanoma.
 
+ Citations + Abstracts
1 Guideline Spitz/Reed nevi: proposal of management recommendations by the Dermoscopy Study Group of the Italian Society of Dermatology (SIDeMaST). 2014

Broganelli, P / Titli, S / Lallas, A / Alaibac M Annetta, A / Battarra, V / Brunetti, B / Castagno, I / Cavicchini, S / Ferrari, A / Ghigliotti, G / Landi, C / Manganoni, A / Moscarella, E / Pellacani, G / Pizzichetta, M A / Rosina, P / Rubegni, P / Satta, R / Scalvenzi, M / Stanganelli, I / Stinco, G / Zalaudek, I / Zampieri, P / Argenziano, G / Anonymous1410806. ·Department of Oncology and Hematology, Section of Dermatology, City of Health and Science Hospital of Turin, Turin, Italy - paolobroganelli@inwind.it. ·G Ital Dermatol Venereol · Pubmed #25213387.

ABSTRACT: -- No abstract --

2 Article Association of CDK4 germline and BRAF somatic mutations in a patient with multiple primary melanomas and BRAF inhibitor resistance. 2015

Governa, Maurizio / Caprarella, Evelina / Dalla Pozza, Edoardo / Vigato, Enrico / Maritan, Monia / Caputo, Glenda G / Zannoni, Marina / Rosina, Paolo / Elefanti, Lisa / Stagni, Camilla / Menin, Chiara. ·Departments of aPlastic and Reconstructive Surgery bPathological Anatomy cMedicine, Section of Dermatology, Azienda Ospedaliera Universitaria Integrata, Verona dUnit of Immunology and Molecular Oncology, Veneto Institute of Oncology, IOV-IRCCS eDepartment of Surgery, Oncology and Gastroenterology, Section of Oncology and Immunology, University of Padova, Padova, Italy. ·Melanoma Res · Pubmed #26110554.

ABSTRACT: Many genetic alterations, including predisposing or somatic mutations, may contribute toward the development of melanoma. Although CDKN2A and CDK4 are high-penetrance genes for melanoma, MC1R is a low-penetrance gene that has been associated most consistently with the disease. Moreover, BRAF is the most frequently somatically altered oncogene and is a validated therapeutic target in melanoma. This paper reports a case of multiple primary melanoma with germline CDK4 mutation, MC1R variant, and somatic BRAF mutation in nine out of 10 melanomas, indicating that a common pathogenesis, because of a predisposing genetic background, may be shared among distinct subsequent melanomas of probable clonal origin. After 3 months of targeted therapy with BRAF inhibitor, our patient developed resistance with rapid progression of the disease leading to death. This is the first case in which early resistance to BRAF inhibitor has been reported in a patient with CDK4 germline mutation.

3 Article Clinical and diagnostic features of in situ melanoma and superficial spreading melanoma: a hospital based study. 2012

Rosina, P / Tessari, G / Giordano, M V / Girolomoni, G. ·Department of Medicine, Section of Dermatology and Venereology, University of Verona, Italy. ·J Eur Acad Dermatol Venereol · Pubmed #21371133.

ABSTRACT: BACKGROUND: Despite the incidence of in situ melanoma is continuously rising; few studies have investigated its clinical and diagnostic features. OBJECTIVE: To investigate clinical and diagnostic features of in situ melanoma compared to superficial spreading melanoma (SSM). METHODS: This is a hospital based, case-control study. Ninety consecutive patients with an in situ melanoma and 90 age and gender matched patients with SSM were enrolled. Main outcome measures were differences in clinical signs that aroused suspicion of in situ melanoma, detection modalities (self-detection vs. incidental detection by a physician), factors conditioning time between first noticing the suspect lesions and the physician visit. RESULTS: Median diameter of in situ melanoma was smaller than SSM (7.5 vs. 9.0 mm, P < 0.024), and 47.8% of in situ melanomas were smaller than 6 mm, in contrast to 25.6% of SSM (P < 0.002). In situ melanoma was mainly detected by a dermatologist (Odds Ratio 2.95 P = 0.018), and in patients with more than 10 melanocytic naevi (Odds Ratio 3.12, P = 0.008). Clinical factors independently associated to early request of dermatological consultation were age older than 45 years (Odds ratio 3.47, P = 0.002) and location of lesion in a difficult observation skin site (Odds ratio 4.20, P = 0.001), but not Breslow's thickness. CONCLUSIONS: Our findings show that in situ melanoma and SSM share similar clinical characteristics and early warning signs. However, in situ melanoma is smaller in size than SSM. This may have important implications for early diagnosis and prevention strategies.